title: Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.
abstract: OBJECTIVE
  Sezary syndrome (SS) and tumor-stage mycosis fungoides (MF) are generally incurable with currently available treatments. We conducted a retrospective study to evaluate the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) in this patient population.
  
  
  METHODS
  From August 1996 through October 2002, eight patients with advanced MF/SS underwent allogeneic HSCT at our institution. All patients were heavily pretreated, having failed a median number of seven prior therapies (range, five to 12). Clonal T-cell populations in peripheral blood or bone marrow were detectable by polymerase chain reaction analyses of T-cell receptor gamma-chain gene rearrangements in six patients and cytogenetics in three patients. The conditioning regimen included total-body irradiation and cyclophosphamide (n = 3), busulfan and cyclophosphamide (n = 1), and the reduced-intensity regimen of fludarabine and melphalan (n = 4). Allogeneic hematopoietic stem cells were obtained from HLA-matched siblings (n = 4) and unrelated donors (n = 4).
  
  
  RESULTS
  All patients achieved complete clinical remission and resolution of molecular and cytogenetic markers of disease within 30 to 60 days after HSCT. Two patients died from transplantation-related complications; graft-versus-host disease (GVHD; n = 1) and respiratory syncytial virus pneumonia (n = 1). With a median follow-up of 56 months, six patients remain alive and without evidence of lymphoma.
  
  
  CONCLUSIONS
  Our results suggest that allogeneic HSCT from both HLA-matched sibling and unrelated donors can induce durable clinical, molecular, and cytogenetic remissions in patients with advanced cutaneous T-cell lymphoma that is refractory to standard therapies.
authors.affiliation: City of Hope Comprehensive Cancer Center, Division of Hematology and Hematopoietic Cell Transplantation, 1500 E Duarte Rd, Duarte, CA 94305, USA. arturo.molina@biogenidec.com
authors.forename: Arturo
authors.initials: A
authors.lastname: Molina
authors.forename: Jasmine
authors.initials: J
authors.lastname: Zain
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Arber
authors.forename: Maria
authors.initials: M
authors.lastname: Angelopolou
authors.forename: Margaret
authors.initials: M
authors.lastname: O'Donnell
authors.forename: Joyce
authors.initials: J
authors.lastname: Murata-Collins
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Forman
authors.forename: Auayporn
authors.initials: A
authors.lastname: Nademanee
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002066:Busulfan / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D012751:Sezary Syndrome / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan